Syndax Just Walked Away From a Billion-Dollar Lung Disease

The company also has a second approved product, Revuforj (revumenib), targeting acute leukemia with multiple late-stage trials expanding into frontline settings. And its newer pipeline additions, including a mutant-selective EGFR inhibitor for lung cancer (SNDX-4321) and a next-generation menin inhibitor for myelofibrosis (SNDX-62122), suggest management has been quietly diversifying for a while now.

BofA Securities reportedly called the post-announcement selloff "overdone," arguing that the IPF program was more of a nice-to-have than a core pillar. That's a fair point. The strategic center of gravity for Syndax has clearly shifted toward hematology-oncology, with cGVHD revenue keeping the lights on while the leukemia programs scale up. Management has said the company is fully funded through profitability, which gives them runway even without an IPF win.

Still, losing a potential blockbuster indication stings. IPF is a multi-billion-dollar market opportunity, and investors had priced in at least some probability of success. That optionality evaporated overnight.

The IPF Battlefield Just Got Messier

Syndax's exit doesn't happen in a vacuum. The IPF treatment landscape in 2026 looks like a poker table where several players just went all-in, and nobody's sure who has the best hand.

The two legacy therapies, nintedanib and pirfenidone, have been the standard of care for years. They slow the disease, but patients still decline, and the side effects (think GI problems) aren't exactly a walk in the park. Everyone agrees better options are needed.

The most important new arrival is nerandomilast (from Boehringer Ingelheim), a PDE4B inhibitor that delivered Phase 3 success and earned U.S. approval in 2025. It's the first truly new mechanism to crack into the IPF category in years, and it's quickly becoming the benchmark that every new contender has to beat.

Then there's Bristol Myers Squibb's admilparant, an oral LPA1 receptor antagonist with a Phase 3 readout that can best be described as "half-great." The 60 mg dose hit its primary endpoint, showing a statistically significant improvement in FVC at Week 52. But the 120 mg dose missed statistical significance, even though it did slow decline. It's like acing one exam and getting a C+ on the other; you passed the class, but the transcript looks weird.

BMS likely has enough data to pursue regulatory approval based on the lower dose, but the inconsistent dose-response leaves room for skeptics. Competitors will be quick to label admilparant as "promising but not fully de-risked."

Beyond these, the pipeline includes inhaled treprostinil (positive Phase 3 signals, different mechanism entirely), deupirfenidone (a next-gen pirfenidone aiming to win on tolerability), and rentosertib (a Phase 3 program with a novel TNIK-targeting approach). The field isn't shrinking; it's fragmenting.

What This Means for Patients (and Investors)

For the roughly 100,000 Americans living with IPF, one fewer clinical program is never good news. Every failed trial means one less shot at a breakthrough. But the silver lining is that the remaining pipeline is genuinely diverse. We're no longer stuck in a world where "antifibrotic" means one of two imperfect drugs.

For investors, the Syndax situation is a textbook lesson in platform risk. Axatilimab works through CSF-1R blockade, essentially targeting a specific receptor on immune cells called macrophages. That mechanism clearly does something useful in cGVHD, where aberrant immune activity drives the disease. But IPF is a different beast. Lung scarring involves a tangled web of fibroblasts, immune cells, and structural damage that no single mechanism has been able to untangle.

Syndax bet that its macrophage-targeting approach could translate across diseases. It couldn't, at least not here. The lesson? Biology doesn't care about your corporate strategy.

The Scoreboard

IPF in late 2026 has three tiers of competition. Tier one is the entrenched old guard: nintedanib and pirfenidone. Tier two is the near-term challengers: nerandomilast (already approved), admilparant (Phase 3, mixed but viable), inhaled treprostinil, and deupirfenidone. Tier three is a crowded bench of Phase 2 and early Phase 3 programs exploring everything from thromboxane receptors to NOX pathways.

Syndax just moved from tier three to the parking lot. The race continues without them, and the patients waiting for better treatments are watching closely.

Novartis Just Bet $7.8 Billion That Your Body Can Build Its Own Medicine

Novartis just paid $575 million upfront for access to Abogen's RNA technology, in a deal worth up to $7.8 billion. The bet: that your own cells can be programmed to build medicines from scratch, starting with a clever new approach to autoimmune disease.